The impact of SARS-CoV-2 immunization on COVID-19 disease course in people with myasthenia gravis.
Muscle Nerve
; 67(5): 412-416, 2023 05.
Article
em En
| MEDLINE
| ID: mdl-36814101
ABSTRACT
INTRODUCTION/AIMS:
There is limited knowledge regarding the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines οn coronavirus disease 2019 (COVID-19) disease course in people with myasthenia gravis. In this study, we aimed to investigate whether SARS-CoV-2 vaccination influences hospitalization and mortality due to COVID-19 in this population.METHODS:
This is a retrospective analysis of administrative data extracted from the Greek nationwide database that holds the COVID-19 disease and vaccination registry, as well as all medical prescription records. The study period extended from the onset of the pandemic (February 2020) until the 10th of January 2022.RESULTS:
We identified 278 people with myasthenia gravis (mean age 58.1 ± 17.2, 47.5% males) who tested positive for SARS-CoV-2. Of those, 139 (50%) were not vaccinated at the time of infection. Multivariable binary logistic regression analysis showed that the probability of hospitalization increased with age (odds ratio [OR] 1.058; 95% confidence interval [CI], 1.036-1.080; p < .001) and immunosuppressive treatment (OR 2.872; 95% CI 1.412-5.839; p = .004), and decreased with vaccination (OR 0.244; 95% CI 0.132-0.453; p < .001). The probability of a fatal outcome increased with age (OR 1.085; 95% CI 1.043-1.129; p < .001) and decreased with vaccination (OR 0.315; 95% CI 0.125-0.791; p = .014).DISCUSSION:
SARS-CoV-2 vaccination significantly reduces hospitalization and mortality due to COVID-19 in people with myasthenia gravis. This study regarding the efficacy of these vaccines, together with previous studies regarding their safety, provide evidence to support their use in people with myasthenia gravis.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
COVID-19
/
Miastenia Gravis
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Female
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article